The role of placebo control in clinical trials for neurodegenerative diseases

被引：0

作者：

Mehta, Arpan R. ^{[1
,2
,3
,4
,5
]}

Carpenter, James R. ^{[1
,6
]}

Nicholas, Jennifer M. ^{[1
,6
]}

Chataway, Jeremy ^{[1
,7
,8
]}

Virgo, Bruce ^{[9
]}

Parmar, Mahesh K. B. ^{[1
]}

Chandran, Siddharthan ^{[1
,2
,3
]}

Pal, Suvankar ^{[1
,10
,11
]}

机构：

[1] UCL, Inst Clin Trials & Methodol, MRC Clin Trials Unit, ACORD, London, England

[2] Univ Edinburgh, Euan MacDonald Ctr MND Res, Ctr Clin Brain Sci, Anne Rowling Regenerat Neurol Clin, Edinburgh, Scotland

[3] Univ Edinburgh, UK Dementia Res Inst, Edinburgh, Scotland

[4] Oxford Univ Hosp NHS Fdn Trust, Oxford, England

[5] Natl Hosp Neurol & Neurosurg, Queen Sq, London, England

[6] London Sch Hyg & Trop Med, Dept Med Stat, London, England

[7] UCL, UCL Queen Sq Inst Neurol, Fac Brain Sci, Queen Sq Multiple Sclerosis Ctr,Dept Neuroinflamma, London, England

[8] Univ Coll London Hosp, Natl Inst Hlth Res, Biomed Res Ctr, London, England

[9] Univ Edinburgh, MND SMART Patient Advisory Grp, Edinburgh, Scotland

[10] Univ Edinburgh, Euan MacDonald Ctr MND Res, Anne Rowling Regenerat Neurol Clin, Edinburgh, Scotland

[11] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh, Scotland

来源：

NATURE MEDICINE | 2023年 / 29卷 / 11期

基金：

英国医学研究理事会;

关键词：

D O I：

10.1038/d41591-023-00080-0

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：2682 / 2683

页数：23

共 50 条

[1] Drugs and clinical trials in neurodegenerative diseases
Stanzione, Paolo
Tropepi, Domenicantonio
[J]. ANNALI DELL ISTITUTO SUPERIORE DI SANITA, 2011, 47 (01): : 49 - 54
[2] Neural Cells for Neurodegenerative Diseases in Clinical Trials
Fan, Yiping
Goh, Eyleen L. K.
Chan, Jerry Kok Yen
[J]. STEM CELLS TRANSLATIONAL MEDICINE, 2023, 12 (08) : 510 - 526
[3] Apathy in Neurodegenerative Diseases: Recommendations on the Design of Clinical Trials
Cummings, Jeffrey
Friedman, Joseph H.
Garibaldi, George
Jones, Martin
Macfadden, Wayne
Marsh, Laura
Robert, Philippe H.
[J]. JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY, 2015, 28 (03) : 159 - 173
[4] Insights into the Disappointing Clinical Trials of Antioxidants in Neurodegenerative Diseases
Shen, Liang
Ji, Hong-Fang
[J]. JOURNAL OF ALZHEIMERS DISEASE, 2010, 19 (04) : 1141 - 1142
[5] Oxidative Stress Treatment for Clinical Trials in Neurodegenerative Diseases
Ienco, Elena Caldarazzo
LoGerfo, Annalisa
Carlesi, Cecilia
Orsucci, Daniele
Ricci, Giulia
Mancuso, Michelangelo
Siciliano, Gabriele
[J]. JOURNAL OF ALZHEIMERS DISEASE, 2011, 24 : 111 - 126
[6] THE ROLE OF THE PLACEBO MECHANISMS IN CLINICAL TRIALS
Rief, W.
Winkler, A.
Doering, B.
[J]. INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE, 2014, 21 : S71 - S71
[7] Perspectives on molecular targeted therapies and clinical trials for neurodegenerative diseases
Katsuno, Masahisa
Tanaka, Fumiaki
Sobue, Gen
[J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2012, 83 (03): : 329 - 335
[8] DISSEMINATION BIAS IN CLINICAL TRIALS OF NEURODEGENERATIVE DISEASES: AN OBSERVATIONAL STUDY
Stefaniak, James D.
Lam, Thomas C. H.
Sim, Naomi E.
Salman, Rustam Al-Shahi
Breen, David P.
[J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2017, 88 : A77 - A77
[9] Biomarkers in clinical trials for neurodegenerative diseases: Regulatory perspectives and requirements
Broich, Karl
Weiergraeber, Marco
Hampel, Harald
[J]. PROGRESS IN NEUROBIOLOGY, 2011, 95 (04) : 498 - 500
[10] PRIMARY ENDPOINTS IN CLINICAL TRIALS FOR NEUROMUSCULAR/NEURODEGENERATIVE DISEASES: A DESCRIPTIVE ANALYSIS
Robinson, Corey
Aiello, Adrienne
Devecseri, Zsuzsanna
[J]. MUSCLE & NERVE, 2015, 52 : S112 - S112

← 1 2 3 4 5 →